NASDAQ:VKTX Viking Therapeutics - VKTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.83 +0.27 (+2.82%) (As of 02/7/2023 03:41 PM ET) Add Compare Share Share Today's Range$9.37▼$9.8550-Day Range$3.55▼$9.5652-Week Range$2.02▼$9.85Volume1.41 million shsAverage Volume1.69 million shsMarket Capitalization$753.86 millionP/E RatioN/ADividend YieldN/APrice Target$12.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Viking Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.0% Upside$12.75 Price TargetShort InterestBearish8.89% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.96Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.88) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector573rd out of 1,029 stocksPharmaceutical Preparations Industry276th out of 504 stocks 3.5 Analyst's Opinion Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.75, Viking Therapeutics has a forecasted upside of 33.0% from its current price of $9.59.Amount of Analyst CoverageViking Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.89% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Viking Therapeutics has recently increased by 4.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViking Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Viking Therapeutics is -0.88. Previous Next 2.8 News and Social Media Coverage News SentimentViking Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Viking Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 35 people have searched for VKTX on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Viking Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 34.71% of the stock of Viking Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viking Therapeutics are expected to decrease in the coming year, from ($0.88) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -11.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -11.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Viking Therapeutics (NASDAQ:VKTX) StockViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.Read More Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Stock News HeadlinesFebruary 7, 2023 | benzinga.comViking Therapeutics's Earnings: A PreviewFebruary 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Agenus (AGEN) and Viking Therapeutics (VKTX)February 7, 2023 | Investing Trends (Ad)GRAPHITE: "Essential for America's National Defense"Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider. February 7, 2023 | americanbankingnews.comViking Therapeutics (VKTX) to Release Earnings on WednesdayFebruary 4, 2023 | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Down 3.5% February 1, 2023 | finance.yahoo.comViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2022 on February 8, 2023January 28, 2023 | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Stock Rating Upgraded by StockNews.comJanuary 16, 2023 | reuters.comVKTX.OQ - | Stock Price & Latest News | ReutersFebruary 7, 2023 | Investing Trends (Ad)GRAPHITE: "Essential for America's National Defense"Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider. January 12, 2023 | finance.yahoo.comIndividual investors account for 50% of Viking Therapeutics, Inc.'s (NASDAQ:VKTX) ownership, while institutions account for 32%January 9, 2023 | finance.yahoo.comViking Therapeutics Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)January 3, 2023 | msn.comAnalyzing Viking Therapeutics's Short InterestJanuary 3, 2023 | seekingalpha.comViking Therapeutics: Booking Profits Following NASH Sympathy MoveDecember 23, 2022 | benzinga.comHere's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth TodayDecember 13, 2022 | seekingalpha.comVKTX Viking Therapeutics, Inc.November 16, 2022 | finance.yahoo.comA Viking Therapeutics, Inc. (NASDAQ:VKTX) insider increased their holdings by 68% last yearOctober 31, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)October 26, 2022 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q3 2022 Earnings Call TranscriptOctober 26, 2022 | msn.comRecap: Viking Therapeutics Q3 EarningsOctober 26, 2022 | finance.yahoo.comViking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 25, 2022 | benzinga.comEarnings Outlook For Viking TherapeuticsOctober 12, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Viking Therapeutics (VKTX)September 11, 2022 | thestreet.comViking Therapeutics (VKTX) Stock Rising on Positive Clinical ResultsSeptember 3, 2022 | nasdaq.comCompanies Like Viking Therapeutics (NASDAQ:VKTX) Are In A Position To Invest In GrowthAugust 30, 2022 | seekingalpha.comViking Therapeutics: Playing Second Fiddle To MadrigalAugust 2, 2022 | finance.yahoo.comViking Therapeutics to Participate in Fireside Chat at BTIG Biotechnology Conference 2022July 19, 2022 | marketwatch.comViking Therapeutics: FDA Lifts Clinical Hold VK0214 StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Company Calendar Last Earnings11/03/2021Today2/07/2023Next Earnings (Confirmed)2/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VKTX CUSIPN/A CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.75 High Stock Price Forecast$15.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+29.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.20% Return on Assets-32.72% Debt Debt-to-Equity RatioN/A Current Ratio11.74 Quick Ratio11.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book3.81Miscellaneous Outstanding Shares76,690,000Free Float72,470,000Market Cap$753.86 million OptionableOptionable Beta0.77 Key ExecutivesBrian LianPresident, Chief Executive Officer & DirectorMarianne ManciniChief Operating OfficerGregory S. ZanteChief Financial OfficerMichael MorneauVice President-Finance & AdministrationKey CompetitorsAltimmuneNASDAQ:ALTMersana TherapeuticsNASDAQ:MRSNEmergent BioSolutionsNYSE:EBSSeres TherapeuticsNASDAQ:MCRBProtagonist TherapeuticsNASDAQ:PTGXView All CompetitorsInsiders & InstitutionsEnvestnet Asset Management Inc.Sold 1,091 shares on 2/7/2023Ownership: 0.020%Cutler Group LLC CABought 12,600 shares on 2/7/2023Ownership: 0.000%Brinker Capital Investments LLCBought 10,055 shares on 2/6/2023Ownership: 0.013%Simplex Trading LLCBought 87,100 shares on 2/2/2023Ownership: 0.000%SG Americas Securities LLCBought 10,684 shares on 2/2/2023Ownership: 0.014%View All Institutional Transactions VKTX Stock - Frequently Asked Questions Should I buy or sell Viking Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VKTX shares. View VKTX analyst ratings or view top-rated stocks. What is Viking Therapeutics' stock price forecast for 2023? 2 brokerages have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price forecasts range from $10.00 to $15.00. On average, they anticipate the company's stock price to reach $12.75 in the next year. This suggests a possible upside of 33.4% from the stock's current price. View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts. How have VKTX shares performed in 2023? Viking Therapeutics' stock was trading at $9.40 at the beginning of the year. Since then, VKTX shares have increased by 1.7% and is now trading at $9.56. View the best growth stocks for 2023 here. When is Viking Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023. View our VKTX earnings forecast. How can I listen to Viking Therapeutics' earnings call? Viking Therapeutics will be holding an earnings conference call on Wednesday, February 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "8094886". How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, November, 3rd. The biotechnology company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO). When did Viking Therapeutics IPO? (VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager. What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." Who are Viking Therapeutics' major shareholders? Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Moody Aldrich Partners LLC (0.26%), Simplex Trading LLC (0.00%), Quantum Private Wealth LLC (0.08%), Titleist Asset Management LTD. (0.02%), Forum Financial Management LP (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr. View institutional ownership trends. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $9.56. How much money does Viking Therapeutics make? Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $733.16 million. The biotechnology company earns $-54,990,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com. This page (NASDAQ:VKTX) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.